Interviewed by Sisterhood editorial board member Daphne Zohar, Kate Haviland talks about the numerous programs that Blueprint created, the rationale behind key go/no-go and partnering decisions, and how she feels about the biotech sector today. Biographies Kate Haviland was the Chief Executive Officer of Blueprint Medicines, which was acquired by Sanofi in 2025 for a total equity value, including potential CVR payments, of approximately $9.5. Previously, she served as Chief

The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community. Coverage brought to you by